Skip to main content
Home > The Daily Extra > Top Story

Chronological Index of : Top Story

 Current Issue
  • TOP STORY: Express Scripts to seek discounts for Repatha, Praluent

    Express Scripts Holding Co. (NASDAQ:ESRX) said its Pharmacy and Therapeutics (P&T) Committee will meet next month to evaluate whether to include PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab in the PBM's …

    Published on 8/28/2015
  • TOP STORY: FDA approves Repatha

    FDA approved a BLA for Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN), making it the second mAb against PCSK9 to gain U.S. approval. FDA approved Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron …

    Published on 8/27/2015
  • TOP STORY: CMS panel backs current Cologuard reimbursement rate

    Exact Sciences Corp. (NASDAQ:EXAS) said CMS's Advisory Panel on Clinical Diagnostic Laboratory Tests voted 11-0, with one abstention, to maintain Medicare's reimbursement rate for Cologuard in 2016 at $492.72 per test.…

    Published on 8/26/2015
  • TOP STORY: Biotechs rise, broader markets post another loss

    Biotech indices posted modest gains on Tuesday, while broader indices ended the day in the red. The day started strong for all equities, although an afternoon slide reversed most of the progress.The BioCentury 100 rose …

    Published on 8/25/2015
  • TOP STORY: Biotechs suffer as wider sell-off mounts

    Although biotech is still outperforming the broader markets this year, the performance gap has continued to narrow after another dismal trading day. On Monday, the BioCentury 100 finished the day down 318.16 (4.6%) to 6…

    Published on 8/24/2015
  • TOP STORY: Novartis gets full rights to ofatumumab from GSK

    Novartis AG (NYSE:NVS; SIX:NOVN) will acquire rights to ofatumumab in all non-oncology indications from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The human mAb against CD20 is in development to treat relapsing-remitting …

    Published on 8/21/2015
  • TOP STORY: Jardiance demonstrates CV benefit in outcomes trial

    Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) said Jardiance empagliflozin in combination with standard of care (SOC) met its primary endpoint of time to first CV event and demonstrated…

    Published on 8/20/2015
  • TOP STORY: China issues new drug approval guidelines

    China's State Council issued new drug approval guidelines Tuesday intended to eliminate China FDA's application backlog by YE16 and ensure that by 2018 review of all marketing applications submitted to CFDA would be …

    Published on 8/19/2015
  • TOP STORY: Omeros soars on Phase II OMS721 data

    Omeros Corp. (NASDAQ:OMER) jumped $10.48 (72%) to $25.03 on Tuesday after reporting data from four patients in an ongoing Phase II dose-escalation trial of OMS721 to treat thrombotic microangiopathies (TMAs) including …

    Published on 8/18/2015
  • TOP STORY: FDA won't demand pre-approval CVOT from Esperion

    Esperion Therapeutics Inc. (NASDAQ:ESPR) rose $7.99 (11%) to $83.50 in after-hours trading on Monday after it said FDA will not require a cardiovascular outcomes trial of ETC-1002 prior to approval for the company's …

    Published on 8/17/2015
  • TOP STORY: Investor group taking WuXi private in $3.3B deal

    WuXi PharmaTech Inc. (NYSE:WX) gained $2.54 to $43.86 on Friday after it agreed to be acquired and taken private by Chairman and CEO Ge Li and an investor group for $46 per ADS, or $3.3 billion. The price represents a …

    Published on 8/14/2015
  • TOP STORY: Roche acquiring GeneWeave

    Roche (SIX:ROG; OTCQX:RHHBY) will acquire diagnostic play GeneWeave Biosciences Inc. (Los Gatos, Calif.) for $190 million up front and up to $235 million in milestones.Roche will gain GeneWeave's vivoDx platform, which …

    Published on 8/13/2015
  • TOP STORY: Global Blood surges after $120M IPO

    Global Blood Therapeutics Inc. (NASDAQ:GBT) jumped $23.11 (116%) to $43.11 in its first day of trading Wednesday after raising $120 million through the sale of 6 million shares at $20 in an IPO underwritten by Morgan …

    Published on 8/12/2015
  • TOP STORY: Celldex drops on delayed Rintega timeline

    Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $4.39 (21%) to $16.96 on news that the company does not expect to submit U.S. and EU regulatory applications for glioblastoma multiforme (GBM) vaccine candidate Rintega …

    Published on 8/11/2015
  • TOP STORY: Editas raises $120M in series B

    Genome editing company Editas Medicine (Cambridge, Mass.) raised $120 million in a series B round led by new investor bng0, a firm that represents multiple family offices including those of Bill Gates. Other new …

    Published on 8/10/2015
  • TOP STORY: District court sides with Amarin in free-speech case

    The U.S. District Court for the Southern District of New York granted preliminary relief to Amarin Corp. plc (NASDAQ:AMRN) allowing the company to engage in "truthful and non-misleading speech" under the First Amendment…

    Published on 8/7/2015
  • TOP STORY: CVS releases 2016 formulary

    Pharmacy benefit manager CVS Health Corp. (NYSE:CVS) released its 2016 formulary, which includes a list of 119 excluded drugs. Multiple sclerosis (MS) drugs Plegridy peginterferon beta-1a from Biogen Inc. (NASDAQ:BIIB) …

    Published on 8/6/2015
  • TOP STORY: Metacrine raises $36M series A

    Metacrine Inc. (San Diego, Calif.) raised $36 million in a series A round with Arch Venture Partners; EcoR1 Capital; Polaris Partners; and venBio. Metacrine has exclusive rights to two preclinical programs developed in …

    Published on 8/5/2015
  • TOP STORY: Shire makes unsolicited $30B bid for Baxalta

    Shire plc (LSE:SHP; NASDAQ:SHPG) fell $14.48 to $253.60 on NASDAQ after disclosing that it made an unsolicited offer to acquire Baxalta Inc. (NYSE:BXLT) in an all-stock transaction valued at about $30 billion. Shire CEO…

    Published on 8/4/2015
  • TOP STORY: Lexicon gains on Phase III carcinoid syndrome data

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) surged $5.16 (61%) to $13.60 on Monday, bringing the company's market cap to $1.4 billion, after telotristat etiprate met the primary endpoint in the Phase III TELESTAR trial …

    Published on 8/3/2015
  • TOP STORY: Express Scripts unveils 2016 formulary

    Pharmacy benefit manager Express Scripts Holding Co. (NASDAQ:ESRX) released a list of 73 therapies it will not cover in 2016. Diabetes drugs Onglyza saxagliptin and Kombiglyze XR from AstraZeneca plc (LSE:AZN; NYSE:AZN…

    Published on 7/31/2015
  • TOP STORY: Galapagos reports additional Phase IIb filgotinib data in RA

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported 24-week data from the Phase IIb DARWIN 1 trial of filgotinib (GLPG0634) to treat rheumatoid arthritis (RA) that suggested a differentiated safety profile; the data …

    Published on 7/30/2015
  • TOP STORY: Mereo raises $119M, acquires three Novartis programs

    Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and …

    Published on 7/29/2015
  • TOP STORY: Sanofi, Regeneron to develop cancer immunotherapies

    Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) entered a five-year deal under which the partners will jointly develop and commercialize immuno-oncology candidates including PD-1 …

    Published on 7/28/2015
  • TOP STORY: Allergan acquires Naurex, divests generics to Teva

    Allergan plc (NYSE:AGN) rose $18.77 to $326.98 on Monday after announcing plans to acquire Naurex Inc. (Evanston, Ill.) for $560 million up front and divest its generics business to Teva Pharmaceutical Industries Ltd. (…

    Published on 7/27/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993